TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tempest Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.60−0.02 (-3.86%)
Close on Oct 19, 2026
- Market cap
- $9.14M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -70.0% | 32.2% | -203.6% | |
| Return on assets | -63.0% | -39.3% | -89.9% | |
| Current ratio | 8.82 | 6.15 | 2.50 | |
| Debt to equity | – | -0.00 | – | |
| Interest coverage | – | – | -128.4× | |
| Capex to revenue | 396.0% | – | – | |
| Diluted shares | 0M | 0M | 4M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Tempest Therapeutics generated $144.23M from operations and spent $1.30M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$144.23M
Used
$1.30M
Capital expenditure$1.30M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-28670.5%
×Asset turnover0.00×
×Equity multiplier-6.33×
=Return on equity, FY2017752.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2017 | -28670.5% | 0.00× | -6.33× | 752.6% |
| FY2016 | -12597.2% | 0.01× | 1.11× | -70.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$26.26M
- Cash generatingOperating cash flow above zero-$26.82M
- Return on assets improvedROA up on the prior year-81.1% → -63.3%
- Earnings backed by cashOperating cash flow above net income-$26.82M vs -$26.26M
- Less leverageLong-term debt to assets fell0.0% → –
- Better liquidityCurrent ratio rose2.21 → 2.50
- No dilutionShare count did not rise2M → 4M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –